nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.10.2018 | Stroke (H Diener, Section Editor)

Impact of Recent Studies for the Treatment of Intracerebral Hemorrhage

verfasst von: Jochen A. Sembill, Hagen B. Huttner, Joji B. Kuramatsu

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The present review will cover most recent and important studies on acute treatment of intracerebral hemorrhage (ICH).

Recent Findings

Overly pessimistic prognostication in ICH may deny meaningful recovery achieved by specialized neurocritical care. Hematoma enlargement represents the most important target of acute ICH care, which is reduced by aggressive blood pressure management (targeting a systolic blood pressure of 140 mmHg) and appropriate hemostatic treatment especially in anticoagulation-associated ICH (INR reversal using prothrombin complex concentrates, eventually idarucizumab, andexanet, or tranexamic acid). Surgical treatment strategies involving fibrinolytics either used for direct hematoma lysis or used for intraventricular clot removal with/without additional lumbar drainage show great promise. Further novel treatment strategies are underway and need validation or evaluation strongly warranting well-designed future ICH research.

Summary

Several randomized and large-sized observational studies have considerably expanded the field and the evidence on how to treat acute ICH patients. Yet, the one breakthrough intervention to improve functional outcome is still missing, though various treatment concepts possibly interacting with one another have been evaluated and such treatment bundle may improve patients’ outcome.

Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009;373(9675):1632–44. https://doi.org/10.1016/s0140-6736(09)60371-8.CrossRefPubMedPubMedCentral

Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344(19):1450–60. https://doi.org/10.1056/nejm200105103441907.CrossRefPubMed

Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, et al. Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol. 2016;15(9):913–24. https://doi.org/10.1016/S1474-4422(16)30073-4.CrossRefPubMed

Sacco S, Marini C, Toni D, Olivieri L, Carolei A. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke. 2009;40(2):394–9. https://doi.org/10.1161/STROKEAHA.108.523209.CrossRefPubMed

van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9(2):167–76. https://doi.org/10.1016/s1474-4422(09)70340-0.CrossRefPubMed

Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032–60. https://doi.org/10.1161/str.0000000000000069.CrossRefPubMed

• Sembill JA, Gerner ST, Volbers B, Bobinger T, Lucking H, Kloska SP, et al. Severity assessment in maximally treated ICH patients: the max-ICH score. Neurology. 2017;89(5):423–31. https://doi.org/10.1212/WNL.0000000000004174. Authors report that overly pessimisitc prognostication may deny a meanignfull recovery and provide a novel prognostic tool.CrossRefPubMed

Zahuranec DB, Brown DL, Lisabeth LD, Gonzales NR, Longwell PJ, Smith MA, et al. Early care limitations independently predict mortality after intracerebral hemorrhage. Neurology. 2007;68(20):1651–7. https://doi.org/10.1212/01.wnl.0000261906.93238.72.CrossRefPubMed

Morgenstern LB, Zahuranec DB, Sanchez BN, Becker KJ, Geraghty M, Hughes R, et al. Full medical support for intracerebral hemorrhage. Neurology. 2015;84(17):1739–44. https://doi.org/10.1212/WNL.0000000000001525.CrossRefPubMedPubMedCentral

10.

Becker KJ, Baxter AB, Cohen WA, Bybee HM, Tirschwell DL, Newell DW, et al. Withdrawal of support in intracerebral hemorrhage may lead to self-fulfilling prophecies. Neurology. 2001;56(6):766–72.CrossRefPubMed

11.

Yogendrakumar V, Smith EE, Demchuk AM, Aviv RI, Rodriguez-Luna D, Molina CA, et al. Lack of early improvement predicts poor outcome following acute intracerebral hemorrhage. Crit Care Med. 2018;46(4):e310–e7. https://doi.org/10.1097/CCM.0000000000002962.CrossRefPubMed

12.

Maas MB, Francis BA, Sangha RS, Lizza BD, Liotta EM, Naidech AM. Refining prognosis for intracerebral hemorrhage by early reassessment. Cerebrovasc Dis. 2017;43(3–4):110–6. https://doi.org/10.1159/000452679000452679.CrossRefPubMed

13.

Suo Y, Chen WQ, Pan YS, Peng YJ, Yan HY, Zhao XQ, Liu LP, Wang YL, Liu GF, Wang YJ The max-intracerebral hemorrhage score predicts long-term outcome of intracerebral hemorrhage. CNS Neurosci Ther. 2018. https://doi.org/10.1111/cns.12846.

14.

Jacobs BS, Poggesi A, Terry JB. Max-ICH score: can it prevent self-fulfilling prophecy in ICH? Neurology. 2017;89(5):417–8. https://doi.org/10.1212/WNL.0000000000004195.CrossRefPubMed

15.

Langhorne P, Fearon P, Ronning OM, Kaste M, Palomaki H, Vemmos K, Kalra L, Indredavik B, Blomstrand C, Rodgers H, Dennis MS, Salman RAS, on behalf of the Stroke Unit Trialists’ Collaboration, The following collaborators provided new data, advice and comment, and assisted with the redrafting of the report:, Blomstrand C, Indredavik B, Kalra L, Kaste M, Palomaki H, Rodgers H, Ronning MO, Vemmos K, The Stroke Unit Trialists’ Collaboration supported and provided for the main stroke unit review:, Asplund K, Berman P, Blomstrand C, Britton M, Cabral NL, Cavallini A, Dey P, Hamrin E, Hankey G, Indredavik B, Kalra L, Kaste M, Laursen SO, Ma RH, Patel N, Rodgers H, Ronning MO, Sivenius J, Stevens R, Sulter G, Svensson A, Vemmos K, Wood-Dauphinee S, Yagura H Stroke unit care benefits patients with intracerebral hemorrhage: systematic review and meta-analysis. Stroke 2013;44(11):3044–3049. https://doi.org/10.1161/STROKEAHA.113.001564 CrossRefPubMed

16.

Damian MS, Ben-Shlomo Y, Howard R, Bellotti T, Harrison D, Griggs K, et al. The effect of secular trends and specialist neurocritical care on mortality for patients with intracerebral haemorrhage, myasthenia gravis and Guillain-Barre syndrome admitted to critical care : an analysis of the Intensive Care National Audit & Research Centre (ICNARC) national United Kingdom database. Intensive Care Med. 2013;39(8):1405–12. https://doi.org/10.1007/s00134-013-2960-6.CrossRefPubMed

17.

Middleton S, McElduff P, Ward J, Grimshaw JM, Dale S, D’Este C, et al. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. Lancet. 2011;378(9804):1699–706. https://doi.org/10.1016/S0140-6736(11)61485-2.CrossRefPubMed

18.

Sreekrishnan A, Leasure AC, Shi FD, Hwang DY, Schindler JL, Petersen NH, et al. Functional improvement among intracerebral hemorrhage (ICH) survivors up to 12 months post-injury. Neurocrit Care. 2017;27(3):326–33. https://doi.org/10.1007/s12028-017-0425-4.CrossRefPubMedPubMedCentral

19.

Delcourt C, Huang Y, Arima H, Chalmers J, Davis SM, Heeley EL, et al. Hematoma growth and outcomes in intracerebral hemorrhage: the INTERACT1 study. Neurology. 2012;79(4):314–9. https://doi.org/10.1212/WNL.0b013e318260cbba.CrossRefPubMed

20.

•• Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313(8):824–36. https://doi.org/10.1001/jama.2015.0846. Large cohort study reporting on both acute and long-term management in anticoaugulation-associated ICH. For the first time provides INR targets to minimize hematoma expansion.CrossRefPubMed

21.

Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, Molina CA, Blas YS, Dzialowski I, et al. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol. 2012;11(4):307–14. https://doi.org/10.1016/S1474-4422(12)70038-8.CrossRefPubMed

22.

Morotti A, Boulouis G, Romero JM, Brouwers HB, Jessel MJ, Vashkevich A, et al. Blood pressure reduction and noncontrast CT markers of intracerebral hemorrhage expansion. Neurology. 2017;89(6):548–54. https://doi.org/10.1212/WNL.0000000000004210.CrossRefPubMedPubMedCentral

23.

Morotti A, Dowlatshahi D, Boulouis G, Al-Ajlan F, Demchuk AM, Aviv RI, et al. Predicting intracerebral hemorrhage expansion with noncontrast computed tomography: the BAT score. Stroke. 2018;49(5):1163–9. https://doi.org/10.1161/STROKEAHA.117.020138.CrossRefPubMedPubMedCentral

24.

Wang X, Arima H, Al-Shahi Salman R, Woodward M, Heeley E, Stapf C, et al. Clinical prediction algorithm (BRAIN) to determine risk of hematoma growth in acute intracerebral hemorrhage. Stroke. 2015;46(2):376–81. https://doi.org/10.1161/STROKEAHA.114.006910.CrossRefPubMed

25.

Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059–64.CrossRefPubMed

26.

Biffi A, Battey TW, Ayres AM, Cortellini L, Schwab K, Gilson AJ, et al. Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology. 2011;77(20):1840–6. https://doi.org/10.1212/WNL.0b013e3182377e12.CrossRefPubMedPubMedCentral

27.

Kobayashi J, Koga M, Tanaka E, Okada Y, Kimura K, Yamagami H, et al. Continuous antihypertensive therapy throughout the initial 24 hours of intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. Stroke. 2014;45(3):868–70. https://doi.org/10.1161/STROKEAHA.113.004319.CrossRefPubMed

28.

Tsivgoulis G, Katsanos AH, Butcher KS, Boviatsis E, Triantafyllou N, Rizos I, et al. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. Neurology. 2014;83(17):1523–9. https://doi.org/10.1212/WNL.0000000000000917.CrossRefPubMed

29.

Butcher KS, Jeerakathil T, Hill M, Demchuk AM, Dowlatshahi D, Coutts SB, et al. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke. 2013;44(3):620–6. https://doi.org/10.1161/strokeaha.111.000188.CrossRefPubMed

30.

Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008;7(5):391–9. https://doi.org/10.1016/S1474-4422(08)70069-3.CrossRefPubMed

31.

Qureshi AI, Palesch YY, Martin R, Novitzke J, Cruz-Flores S, Ehtisham A, et al. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol. 2010;67(5):570–6. https://doi.org/10.1001/archneurol.2010.61.CrossRefPubMedPubMedCentral

32.

Anderson CS, Huang Y, Arima H, Heeley E, Skulina C, Parsons MW, et al. Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke. 2010;41(2):307–12. https://doi.org/10.1161/strokeaha.109.561795.CrossRefPubMed

33.

•• Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355–65. https://doi.org/10.1056/NEJMoa1214609. Randomized controlled trial showing improved functional outcomes with intensive lowering of blood pressure among ordinal analysis of the modified Rankin scale.CrossRefPubMed

34.

•• Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375(11):1033–43. https://doi.org/10.1056/NEJMoa1603460. Most recent randomized controlled trial documenting no significant benefit of intensive blood pressure lowering.CrossRefPubMedPubMedCentral

35.

Burgess LG, Goyal N, Jones GM, Khorchid Y, Kerro A, Chapple K et al. Evaluation of acute kidney injury and mortality after intensive blood pressure control in patients with intracerebral hemorrhage. J Am Heart Assoc. 2018;7(8). https://doi.org/10.1161/JAHA.117.008439.CrossRefPubMedPubMedCentral

36.

Morotti A, Brouwers HB, Romero JM, Jessel MJ, Vashkevich A, Schwab K, et al. Intensive blood pressure reduction and spot sign in intracerebral hemorrhage: a secondary analysis of a randomized clinical trial. JAMA Neurol. 2017;74(8):950–60. https://doi.org/10.1001/jamaneurol.2017.1014.CrossRefPubMedPubMedCentral

37.

Shoamanesh A, Morotti A, Romero JM, Oliveira-Filho J, Schlunk F, Jessel MJ, et al. Cerebral microbleeds and the effect of intensive blood pressure reduction on hematoma expansion and functional outcomes: a secondary analysis of the ATACH-2 randomized clinical trial. JAMA Neurol. 2018;75:850–9. https://doi.org/10.1001/jamaneurol.2018.0454.CrossRefPubMedPubMedCentral

38.

Qureshi AI, Palesch YY, Foster LD, Barsan WG, Goldstein JN, Hanley DF, et al. Blood pressure-attained analysis of ATACH 2 trial. Stroke. 2018;49(6):1412–8. https://doi.org/10.1161/STROKEAHA.117.019845.CrossRefPubMedPubMedCentral

39.

•• Boulouis G, Morotti A, Goldstein JN, Charidimou A. Intensive blood pressure lowering in patients with acute intracerebral haemorrhage: clinical outcomes and haemorrhage expansion. Systematic review and meta-analysis of randomised trials. J Neurol Neurosurg Psychiatry. 2017;88(4):339–45. https://doi.org/10.1136/jnnp-2016-315346. Meta-analysis of randomized data ( n = 4360) investigating the effect of intensive blood pressure reductions on outcomes.CrossRefPubMed

40.

• Morotti A, Charidimou A, Phuah CL, Jessel MJ, Schwab K, Ayres AM, et al. Association between serum calcium level and extent of bleeding in patients with intracerebral hemorrhage. JAMA Neurol. 2016;73(11):1285–90. https://doi.org/10.1001/jamaneurol.2016.22522546924. Authors report on a novel parameter associated with ICH volumes.CrossRefPubMedPubMedCentral

41.

Liotta EM, Prabhakaran S, Sangha RS, Bush RA, Long AE, Trevick SA, et al. Magnesium, hemostasis, and outcomes in patients with intracerebral hemorrhage. Neurology. 2017;89(8):813–9. https://doi.org/10.1212/WNL.0000000000004249.CrossRefPubMedPubMedCentral

42.

Goyal N, Tsivgoulis G, Malhotra K, Houck AL, Khorchid YM, Pandhi A et al. Serum magnesium levels and outcomes in patients with acute spontaneous intracerebral hemorrhage. J Am Heart Assoc. 2018;7(8). https://doi.org/10.1161/JAHA.118.008698 CrossRefPubMedPubMedCentral

43.

Hoffman M, Monroe DM 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9(Suppl 1):S61–5.PubMed

44.

Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352(8):777–85. https://doi.org/10.1056/NEJMoa042991.CrossRefPubMed

45.

Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358(20):2127–37. https://doi.org/10.1056/NEJMoa0707534.CrossRefPubMed

46.

Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17(10):1–79. https://doi.org/10.3310/hta17100.CrossRefPubMedPubMedCentral

47.

•• Sprigg N, Flaherty K, Appleton JP, Salman RA, Bereczki D, Beridze M, et al. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet. 2018;391:2107–15. https://doi.org/10.1016/S0140-6736(18)31033-X. Randomized controlled trial on effects of tranexamic acid in ICH patients showing a decreased early (7 days) mortality, reduced hematoma enlargement, and a favorable safety profile for tranexamic acid. Sub-group analyses favored treatment in patients with systolic blood pressures below 170 mmHg, lobar ICH location, and ICH volumes between 30 and 60 mL.CrossRefPubMedPubMedCentral

48.

Meretoja A, Churilov L, Campbell BC, Aviv RI, Yassi N, Barras C, et al. The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial. Int J Stroke. 2014;9(4):519–24. https://doi.org/10.1111/ijs.12132.CrossRefPubMed

49.

Liu L, Wang Y, Meng X, Li N, Tan Y, Nie X, et al. Tranexamic acid for acute intracerebral hemorrhage growth predicted by spot sign trial: rationale and design. Int J Stroke. 2017;12(3):326–31. https://doi.org/10.1177/1747493017694394.CrossRefPubMed

50.

Brouwers HB, Chang Y, Falcone GJ, Cai X, Ayres AM, Battey TW, et al. Predicting hematoma expansion after primary intracerebral hemorrhage. JAMA Neurol. 2014;71(2):158–64. https://doi.org/10.1001/jamaneurol.2013.5433.CrossRefPubMedPubMedCentral

51.

• Steiner T, Poli S, Griebe M, Husing J, Hajda J, Freiberger A, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15(6):566–73. https://doi.org/10.1016/S1474-4422(16)00110-1. Randomized controlled trial comparing PCC versus FFP in VKA ICH patients providing evidence in favor of PCC for reversal of anticoagulation.CrossRefPubMed

52.

Kuramatsu JB, Sembill JA, Gerner ST, Sprugel MI, Hagen M, Roeder SS, et al. Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves. Eur Heart J. 2018;39:1709–23. https://doi.org/10.1093/eurheartj/ehy056.CrossRefPubMedPubMedCentral

53.

• Gerner ST, Kuramatsu JB, Sembill JA, Sprugel MI, Endres M, Haeusler KG, et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol. 2018;83(1):186–96. https://doi.org/10.1002/ana.25134. Large cohort study reporting on reversal strategies in non-vitamin K anticoaugulation-associated ICH.CrossRefPubMed

54.

Purrucker JC, Haas K, Rizos T, Khan S, Wolf M, Hennerici MG, et al. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. JAMA Neurol. 2016;73(2):169–77. https://doi.org/10.1001/jamaneurol.2015.3682.CrossRefPubMed

55.

Boulouis G, Morotti A, Pasi M, Goldstein JN, Gurol ME, Charidimou A. Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89(3):263–70. https://doi.org/10.1136/jnnp-2017-316631.CrossRefPubMed

56.

Wilson D, Seiffge DJ, Traenka C, Basir G, Purrucker JC, Rizos T, et al. Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurology. 2017;88(18):1693–700. https://doi.org/10.1212/WNL.0000000000003886.CrossRefPubMedPubMedCentral

57.

Kurogi R, Nishimura K, Nakai M, Kada A, Kamitani S, Nakagawara J, et al. Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin. Neurology. 2018;90(13):e1143–e9. https://doi.org/10.1212/WNL.0000000000005207.CrossRefPubMedPubMedCentral

58.

Tsivgoulis G, Lioutas VA, Varelas P, Katsanos AH, Goyal N, Mikulik R, et al. Direct oral anticoagulant- vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage. Neurology. 2017;89(11):1142–51. https://doi.org/10.1212/WNL.0000000000004362.CrossRefPubMed

59.

Inohara T, Xian Y, Liang L, Matsouaka RA, Saver JL, Smith EE, et al. Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality. JAMA. 2018;319(5):463–73. https://doi.org/10.1001/jama.2017.21917.CrossRefPubMedPubMedCentral

60.

Ebner M, Birschmann I, Peter A, Spencer C, Hartig F, Kuhn J, et al. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Crit Care. 2017;21(1):32. https://doi.org/10.1186/s13054-017-1619-z.CrossRefPubMedPubMedCentral

61.

•• Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431–41. https://doi.org/10.1056/NEJMoa1707278. Full cohort analysis of idarucizumab for dabigatran reversal.CrossRefPubMed

62.

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–41. https://doi.org/10.1056/NEJMoa1607887.CrossRefPubMedPubMedCentral

63.

Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373(25):2413–24. https://doi.org/10.1056/NEJMoa1510991.CrossRefPubMed

64.

• Baharoglu MI, Cordonnier C, Salman RA, de Gans K, Koopman MM, Brand A, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387(10038):2605–13. https://doi.org/10.1016/S0140-6736(16)30392-0. Randomized controlled trial investigating platelet transfusions in ICH patients using platelet inhibitors, showing evidence in disfavor of platelet transfusions.CrossRefPubMed

65.

Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005;365(9457):387–97. https://doi.org/10.1016/s0140-6736(05)17826-x.CrossRefPubMed

66.

Mendelow AD, Gregson BA, Rowan EN, Murray GD, Gholkar A, Mitchell PM. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet. 2013;382(9890):397–408. https://doi.org/10.1016/s0140-6736(13)60986-1.CrossRefPubMedPubMedCentral

67.

•• Hanley DF, Thompson RE, Muschelli J, Rosenblum M, McBee N, Lane K, et al. Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial. Lancet Neurol. 2016;15(12):1228–37. https://doi.org/10.1016/s1474-4422(16)30234-4. Randomized controlled trial investigating intraventricular thrombolysis, showing a reduced mortality at 180 days, a safe profile, and faster clot removal which was associated with favorable functional outcome.CrossRefPubMedPubMedCentral

68.

van Loon J, Van Calenbergh F, Goffin J, Plets C. Controversies in the management of spontaneous cerebellar haemorrhage. A consecutive series of 49 cases and review of the literature. Acta Neurochir. 1993;122(3–4):187–93.CrossRefPubMed

69.

Firsching R, Huber M, Frowein RA. Cerebellar haemorrhage: management and prognosis. Neurosurg Rev. 1991;14(3):191–4.CrossRefPubMed

70.

Tamaki T, Kitamura T, Node Y, Teramoto A. Paramedian suboccipital mini-craniectomy for evacuation of spontaneous cerebellar hemorrhage. Neurol Med Chir (Tokyo). 2004;44(11):578–82. discussion 83CrossRef

71.

Hackenberg KA, Unterberg AW, Jung CS, Bosel J, Schonenberger S, Zweckberger K. Does suboccipital decompression and evacuation of intraparenchymal hematoma improve neurological outcome in patients with spontaneous cerebellar hemorrhage? Clin Neurol Neurosurg. 2017;155:22–9. https://doi.org/10.1016/j.clineuro.2017.01.019.CrossRefPubMed

72.

Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–e110. https://doi.org/10.1161/STR.0000000000000158.CrossRefPubMed

73.

Volbers B, Giede-Jeppe A, Gerner ST, Sembill JA, Kuramatsu JB, Lang S, et al. Peak perihemorrhagic edema correlates with functional outcome in intracerebral hemorrhage. Neurology. 2018;90(12):e1005–e12. https://doi.org/10.1212/WNL.0000000000005167.CrossRefPubMed

74.

Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006;5(1):53–63. https://doi.org/10.1016/s1474-4422(05)70283-0.CrossRefPubMed

75.

Wang X, Arima H, Yang J, Zhang S, Wu G, Woodward M, et al. Mannitol and outcome in intracerebral hemorrhage: propensity score and multivariable intensive blood pressure reduction in acute cerebral hemorrhage trial 2 results. Stroke. 2015;46(10):2762–7. https://doi.org/10.1161/STROKEAHA.115.009357.CrossRefPubMed

76.

Shah M, Birnbaum L, Rasmussen J, Sekar P, Moomaw CJ, Osborne J, et al. Effect of hyperosmolar therapy on outcome following spontaneous intracerebral hemorrhage: Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) study. J Stroke Cerebrovasc Dis. 2018;27(4):1061–7. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.11.013.CrossRefPubMedPubMedCentral

77.

Volbers B, Herrmann S, Willfarth W, Lucking H, Kloska SP, Doerfler A, et al. Impact of hypothermia initiation and duration on perihemorrhagic edema evolution after intracerebral hemorrhage. Stroke. 2016;47(9):2249–55. https://doi.org/10.1161/STROKEAHA.116.013486.CrossRefPubMed

78.

Staykov D, Wagner I, Volbers B, Doerfler A, Schwab S, Kollmar R. Mild prolonged hypothermia for large intracerebral hemorrhage. Neurocrit Care. 2013;18(2):178–83. https://doi.org/10.1007/s12028-012-9762-5.CrossRefPubMed

79.

Rincon F, Friedman DP, Bell R, Mayer SA, Bray PF. Targeted temperature management after intracerebral hemorrhage (TTM-ICH): methodology of a prospective randomized clinical trial. Int J Stroke. 2014;9(5):646–51. https://doi.org/10.1111/ijs.12220.CrossRefPubMed

80.

Fischer M, Schiefecker A, Lackner P, Frank F, Helbok R, Beer R, et al. Targeted temperature management in spontaneous intracerebral hemorrhage: a systematic review. Curr Drug Targets. 2017;18(12):1430–40. https://doi.org/10.2174/1389450117666160703161511.CrossRefPubMed

81.

Zeng L, Tan L, Li H, Zhang Q, Li Y, Guo J. Deferoxamine therapy for intracerebral hemorrhage: a systematic review. PLoS One. 2018;13(3):e0193615. https://doi.org/10.1371/journal.pone.0193615.CrossRefPubMedPubMedCentral

82.

Fu Y, Hao J, Zhang N, Ren L, Sun N, Li YJ, et al. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol. 2014;71(9):1092–101. https://doi.org/10.1001/jamaneurol.2014.1065.CrossRefPubMed

83.

Morgan T, Awad I, Keyl P, Lane K, Hanley D. Preliminary report of the clot lysis evaluating accelerated resolution of intraventricular hemorrhage (CLEAR-IVH) clinical trial. Acta Neurochir Suppl. 2008;105:217–20.CrossRefPubMed

84.

Hanley DF, Lane K, McBee N, Ziai W, Tuhrim S, Lees KR, et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet. 2017;389(10069):603–11. https://doi.org/10.1016/S0140-6736(16)32410-2.CrossRefPubMedPubMedCentral

85.

Staykov D, Huttner HB, Struffert T, Ganslandt O, Doerfler A, Schwab S, et al. Intraventricular fibrinolysis and lumbar drainage for ventricular hemorrhage. Stroke. 2009;40(10):3275–80. https://doi.org/10.1161/strokeaha.109.551945.CrossRefPubMed

86.

Huttner HB, Nagel S, Tognoni E, Kohrmann M, Juttler E, Orakcioglu B, et al. Intracerebral hemorrhage with severe ventricular involvement: lumbar drainage for communicating hydrocephalus. Stroke. 2007;38(1):183–7. https://doi.org/10.1161/01.str.0000251795.02560.62.CrossRefPubMed

87.

• Staykov D, Kuramatsu JB, Bardutzky J, Volbers B, Gerner ST, Kloska SP, et al. Efficacy and safety of combined intraventricular fibrinolysis with lumbar drainage for prevention of permanent shunt dependency after intracerebral hemorrhage with severe ventricular involvement: a randomized trial and individual patient data meta-analysis. Ann Neurol. 2017;81(1):93–103. https://doi.org/10.1002/ana.24834. Small randomized controlled trial and meta-analyses investigating the influence of lumbar drains on permanent shunt dependency.CrossRefPubMed

88.

Murthy SB, Awad I, Harnof S, Aldrich F, Harrigan M, Jallo J, et al. Permanent CSF shunting after intraventricular hemorrhage in the CLEAR III trial. Neurology. 2017;89(4):355–62. https://doi.org/10.1212/WNL.0000000000004155.CrossRefPubMedPubMedCentral

Titel: Impact of Recent Studies for the Treatment of Intracerebral Hemorrhage
verfasst von: Jochen A. Sembill
Hagen B. Huttner
Joji B. Kuramatsu
Publikationsdatum: 01.10.2018
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 10/2018
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-018-0872-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Impact of Recent Studies for the Treatment of Intracerebral Hemorrhage

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2018

Management of Brain Metastases in the New Era of Checkpoint Inhibition

Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors

Does Dexmedetomidine Ameliorate Postoperative Cognitive Dysfunction? A Brief Review of the Recent Literature

Circadian Rhythm Disturbances in the Blind

Sleep-Wake Disorders in Stroke—Increased Stroke Risk and Deteriorated Recovery? An Evaluation on the Necessity for Prevention and Treatment

Detection of Atrial Fibrillation in Cryptogenic Stroke

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie